PMV Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a precision oncology company that pioneers the discovery and development of small-molecule, tumor-agnostic therapies targeting p53 mutations prevalent in approximately half of all human cancers. Founded in 2013 and headquartered in Princeton, New Jersey, the company focuses on restoring the tumor-suppressing function of mutated p53 proteins through structural correction, with operations centered in the United States and global clinical trial sites across the U.S., Europe, U.K., and Asia-Pacific. Its lead product candidate, rezatapopt (PC14586), is an orally available, first-in-class selective p53 Y220C reactivator in Phase 2 pivotal development under the PYNNACLE trial (NCT04585750) for advanced solid tumors harboring the TP53 Y220C mutation and KRAS wild-type status, including cohorts for ovarian, lung, breast, endometrial cancers, and other solid tumors; the U.S. FDA has granted Fast Track designation to rezatapopt for locally advanced or metastatic solid tumors with p53 Y220C. The pipeline also includes an investigator-initiated Phase 1b study of rezatapopt monotherapy and in combination with azacitidine for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with p53 Y220C, conducted in collaboration with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center; plus undisclosed early-stage programs targeting other p53 hotspot mutations and solid tumors. Recent advancements include over 90% site activation for the Phase 2 PYNNACLE monotherapy trial with interim data expected mid-2025; promising Phase 1 PYNNACLE results showing confirmed partial responses in 7 of 15 ovarian cancer patients (median duration seven months) and 3 of 8 breast cancer patients; discontinuation of the rezatapopt plus KEYTRUDA (pembrolizumab) combination arm due to insufficient clinical benefit; a partnership with Foundation Medicine for companion diagnostic development of FoundationOne CDx to identify p53 Y220C patients; enrollment commencement in the MD Anderson Phase 1b AML/MDS study; presentation of ovarian and breast cancer data at the 2024 Society for Gynecologic Oncology and San Antonio Breast Cancer Symposiums, respectively; and publication of rezatapopt discovery in ACS Medicinal Chemistry Letters, with the company reporting a $183.3 million cash position as of December 31, 2024, supporting operations through 2026 alongside a reduced net loss of $58.7 million for the year.
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PMV Pharmaceuticals Announces Board Chair Transition
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer